Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice

International Journal of Obesity

Volumn 37, Issue 2, 2013, Pages 279-287

  Verty, A N A ^a   Lockie, S H ^a   Stefanidis, A ^a   Oldfield, B J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

cannabinoids; energy expenditure; lipolysis; MCH; thermogenesis

Indexed keywords

ANTIOBESITY AGENT; RIMONABANT; SNAP 94847; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CELL SIZE; CONTROLLED STUDY; DOSE RESPONSE; ENERGY EXPENDITURE; FAT MASS; FOOD INTAKE; FORCED SWIMMING TEST; LIPID METABOLISM; LIPOLYSIS; MALE; MONOTHERAPY; MOOD; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; THERMOGENESIS; WEIGHT CONTROL; WHITE ADIPOSE TISSUE;

ADIPOSE TISSUE, BROWN; ADIPOSE TISSUE, WHITE; AFFECT; ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; DRUG THERAPY, COMBINATION; HYPOTHALAMIC HORMONES; LIPOLYSIS; MALE; MELANINS; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; PHYSICAL CONDITIONING, ANIMAL; PIPERIDINES; PITUITARY HORMONES; PYRAZOLES; THERMOGENESIS; WEIGHT LOSS;

MUS;

EID: 84873731274     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2012.35     Document Type: Article

References (41)

1. Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006; 5: 919-931.
2. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-244.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638.
4. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121-2134.
5. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkal S, Jaral Z et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
6. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977.
7. Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 2002; 8: 825-830.
8. Verty ANA, Allen AM, Oldfield BJ. The Endogenous Actions of Hypothalamic Peptides on Brown Adipose Tissue Thermogenesis in the Rat. Endocrinology 2010; 151: 4236-4246.
9. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melaninconcentrating hormone are hypophagic and lean. Nature 1998; 396: 670-674.
10. Georgescu D, Sears RM, Hommel JD, Barrot M, Bolañ os CA, Marsh DJ et al. The hypothalamic neuropeptide melanin-concentrating hormone acts in the nucleus accumbens to modulate feeding behavior and forced-swim performance. J Neurosci 2005; 25: 2933-2940.
11. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
12. Huang H, Acuna-Goycolea C, Li Y, Cheng HM, Obrietan K, van den Pol AN. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal. J Neurosci 2007; 27: 4870-4871.
13. Verty ANA, Boon WM, Mallet PE, McGregor IS, Oldfield BJ. Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716). Eur J Neurosci 2009; 29: 2207-2216.
14. Verty ANA, Allen AM, Oldfield BJ. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity 2009; 17: 254-261.
15. Stefanidis A, Verty ANA, Allen AM, Owens NC, Cowley MA, Oldfield BJ. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity 2009; 17: 16-24.
16. Verty ANA, McFarlane JR, McGregor IS, Mallet PE. Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004; 145: 3224-3231.
17. Verty ANA, McGregor IS, Mallet PE. Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 2004; 354: 217-220.
18. Verty ANA, McGregor IS, Mallet PE. Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 2004; 47: 593-603.
19. Verty ANA, Singh ME, McGregor IS, Mallet PE. The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology 2003; 168: 314-323.
20. Bermudez-Silva FJ, Viveros MP, McPartland JM, Rodriguez de Fonseca F. The endocannabinoid system, eating behavior and energy homeostasis: the end or a new beginning? Pharmacol Biochem Behav 2010; 95: 375-382.
21. Pissios P. Animals models of MCH function and what they can tell us about its role in energy balance. Peptides 2009; 30: 2040-2044.
22. Cannon B, Nedergaard J. Brown adipose tissue: Function and physiological significance. Physiol Rev 2004; 84: 277-359.
23. Saely CH, Geiger K, Drexel H. Brown versus White Adipose Tissue: A Mini-Review. Gerontology 2012; 58: 15-23.
24. Quarta C, Bellocchio L, Mancini G, Mazza R, Cervino C, Braulke LJ et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 2010; 11: 273-285.
25. Jo YH, Chen YJ, Chua SCJ, Talmage DA, Role LW. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005; 48: 1055-1066.
26. Lihn AS, Jessen N, Pedersen SB, Lund S, Richelsen B. AICAR stimulates adiponectin and inhibits cytokines in adipose tissue. Biochem Biophys Res Commun 2004; 316: 853-858.
27. Perwitz N, Wenzel J, Wagner I, Büning J, Drenckhan M, Zarse K et al. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes Metab 2010; 12: 158-166.
28. Thornton C, Sardini A, Carling D. Muscarinic receptor activation of AMP-activated protein kinase inhibits orexigenic neuropeptide mRNA expression. J Biol Chem 2008; 283: 17116-17122.
29. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
30. Kim JY, Nolte LA, Hansen PA, Han DH, Ferguson K, Thompson PA et al. High-fat diet-induced muscle insulin resistance: relationship to visceral fat mass. Am J Physiol Regul Integr Comp Physiol 2000; 279: R2057-R2065.
31. Sindelka G, Skrha J, Prázn M, Haas T. Association of obesity, diabetes, serum lipids and blood pressure regulates insulin action. Physiol Res 2002; 51: 85-91.
32. Heiling VJ, Miles JM, Jensen MD. How valid are isotopic measurements of fatty acid oxidation? Am J Physiol Regul Integr Comp Physiol 1991; 261: E572-E577.
33. Jensen MD. Diet effects on fatty acid metabolism in lean and obese humans. Am J Clin Nutr 1998; 67 (3 Suppl): 531S-534S.
34. Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab 2008; 93 (11 Suppl 1): S74-S80.
35. Johansson K, Neovius K, DeSantis SM, Rö ssner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: A meta-analysis. Obes Rev 2009; 10: 564-575.
36. André A, Gonthier MP. The endocannabinoid system: Its roles in energy balance and potential as a target for obesity treatment. Int J Biochem Cell Biol 2010; 42: 1788-1801.
37. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-1936.
38. Sears RM, Liu RJ, Narayanan NS, Sharf R, Yeckel MF, Laubach M et al. Regulation of nucleus accumbens activity by the hypothalamic neuropeptide melaninconcentrating hormone. J Neurosci 2010; 30: 8263-8273.
39. Kalueff AV, Wheaton M, Murphy DL. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res 2007; 179: 1-18.
40. Takahashi E, Katayama M, Niimi K, Itakura C. Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests. Eur J Pharmacol 2008; 589: 149-156.
41. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003; 138: 544-553.